nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—CHEK2—stomach cancer	0.292	0.655	CbGaD
Gefitinib—EGFR—stomach cancer	0.117	0.262	CbGaD
Gefitinib—EGFR—Docetaxel—stomach cancer	0.083	0.297	CbGbCtD
Gefitinib—ALB—stomach cancer	0.0371	0.0834	CbGaD
Gefitinib—ABCB1—Mitomycin—stomach cancer	0.0263	0.0941	CbGbCtD
Gefitinib—ABCG2—Irinotecan—stomach cancer	0.0187	0.067	CbGbCtD
Gefitinib—ABCG2—Fluorouracil—stomach cancer	0.0179	0.0643	CbGbCtD
Gefitinib—ABCG2—Docetaxel—stomach cancer	0.0137	0.0491	CbGbCtD
Gefitinib—ALB—Irinotecan—stomach cancer	0.0129	0.0462	CbGbCtD
Gefitinib—ALB—Fluorouracil—stomach cancer	0.0124	0.0443	CbGbCtD
Gefitinib—CYP2C9—Capecitabine—stomach cancer	0.0112	0.0403	CbGbCtD
Gefitinib—CYP3A5—Irinotecan—stomach cancer	0.0104	0.0371	CbGbCtD
Gefitinib—ABCG2—Doxorubicin—stomach cancer	0.0102	0.0366	CbGbCtD
Gefitinib—ABCG2—Methotrexate—stomach cancer	0.00989	0.0354	CbGbCtD
Gefitinib—CYP3A5—Docetaxel—stomach cancer	0.00759	0.0272	CbGbCtD
Gefitinib—ALB—Methotrexate—stomach cancer	0.00682	0.0244	CbGbCtD
Gefitinib—ABCB1—Irinotecan—stomach cancer	0.00674	0.0241	CbGbCtD
Gefitinib—CYP2C9—Fluorouracil—stomach cancer	0.00667	0.0239	CbGbCtD
Gefitinib—ABCB1—Docetaxel—stomach cancer	0.00494	0.0177	CbGbCtD
Gefitinib—CYP3A4—Irinotecan—stomach cancer	0.00404	0.0145	CbGbCtD
Gefitinib—ABCB1—Doxorubicin—stomach cancer	0.00368	0.0132	CbGbCtD
Gefitinib—ABCB1—Methotrexate—stomach cancer	0.00357	0.0128	CbGbCtD
Gefitinib—CYP2D6—Doxorubicin—stomach cancer	0.00347	0.0124	CbGbCtD
Gefitinib—ORM1—bile—stomach cancer	0.00346	0.0684	CbGeAlD
Gefitinib—CYP3A4—Docetaxel—stomach cancer	0.00296	0.0106	CbGbCtD
Gefitinib—CYP3A4—Doxorubicin—stomach cancer	0.00221	0.0079	CbGbCtD
Gefitinib—CHEK2—Paclitaxel—Docetaxel—stomach cancer	0.00125	0.608	CbGdCrCtD
Gefitinib—HIPK4—endocrine gland—stomach cancer	0.00103	0.0204	CbGeAlD
Gefitinib—CHEK2—bone marrow—stomach cancer	0.00102	0.0201	CbGeAlD
Gefitinib—IRAK4—hematopoietic system—stomach cancer	0.00099	0.0195	CbGeAlD
Gefitinib—ERBB3—hematopoietic system—stomach cancer	0.00097	0.0192	CbGeAlD
Gefitinib—Lapatinib—ERBB2—stomach cancer	0.000968	0.193	CrCbGaD
Gefitinib—ORM1—gall bladder—stomach cancer	0.000961	0.019	CbGeAlD
Gefitinib—IRAK1—hematopoietic system—stomach cancer	0.000923	0.0182	CbGeAlD
Gefitinib—MKNK2—hematopoietic system—stomach cancer	0.000923	0.0182	CbGeAlD
Gefitinib—MKNK1—hematopoietic system—stomach cancer	0.000911	0.018	CbGeAlD
Gefitinib—ERBB3—epithelium—stomach cancer	0.000887	0.0175	CbGeAlD
Gefitinib—MKNK2—epithelium—stomach cancer	0.000843	0.0167	CbGeAlD
Gefitinib—ALB—gall bladder—stomach cancer	0.000843	0.0166	CbGeAlD
Gefitinib—CSNK1E—pancreas—stomach cancer	0.000819	0.0162	CbGeAlD
Gefitinib—EPHA6—endocrine gland—stomach cancer	0.000817	0.0161	CbGeAlD
Gefitinib—MKNK2—smooth muscle tissue—stomach cancer	0.000813	0.016	CbGeAlD
Gefitinib—IRAK1—smooth muscle tissue—stomach cancer	0.000813	0.016	CbGeAlD
Gefitinib—ERBB3—pancreas—stomach cancer	0.00079	0.0156	CbGeAlD
Gefitinib—MKNK2—pancreas—stomach cancer	0.000751	0.0148	CbGeAlD
Gefitinib—IRAK1—pancreas—stomach cancer	0.000751	0.0148	CbGeAlD
Gefitinib—STK10—hematopoietic system—stomach cancer	0.00075	0.0148	CbGeAlD
Gefitinib—SBK1—lymph node—stomach cancer	0.000723	0.0143	CbGeAlD
Gefitinib—CSNK1E—digestive system—stomach cancer	0.000699	0.0138	CbGeAlD
Gefitinib—IRAK4—lymphoid tissue—stomach cancer	0.000697	0.0138	CbGeAlD
Gefitinib—Afatinib—ERBB2—stomach cancer	0.000686	0.137	CrCbGaD
Gefitinib—ERBB3—lymphoid tissue—stomach cancer	0.000683	0.0135	CbGeAlD
Gefitinib—ERBB3—digestive system—stomach cancer	0.000675	0.0133	CbGeAlD
Gefitinib—MKNK2—lymphoid tissue—stomach cancer	0.00065	0.0128	CbGeAlD
Gefitinib—MKNK2—digestive system—stomach cancer	0.000642	0.0127	CbGeAlD
Gefitinib—MKNK1—lymphoid tissue—stomach cancer	0.000641	0.0127	CbGeAlD
Gefitinib—IRAK4—bone marrow—stomach cancer	0.000635	0.0125	CbGeAlD
Gefitinib—MKNK1—digestive system—stomach cancer	0.000633	0.0125	CbGeAlD
Gefitinib—CHEK2—lymph node—stomach cancer	0.00063	0.0124	CbGeAlD
Gefitinib—MKNK2—bone marrow—stomach cancer	0.000591	0.0117	CbGeAlD
Gefitinib—IRAK1—bone marrow—stomach cancer	0.000591	0.0117	CbGeAlD
Gefitinib—MKNK1—bone marrow—stomach cancer	0.000584	0.0115	CbGeAlD
Gefitinib—CSNK1E—endocrine gland—stomach cancer	0.000578	0.0114	CbGeAlD
Gefitinib—ERBB3—endocrine gland—stomach cancer	0.000558	0.011	CbGeAlD
Gefitinib—Vandetanib—FYN—stomach cancer	0.000556	0.111	CrCbGaD
Gefitinib—ORM1—hematopoietic system—stomach cancer	0.000544	0.0107	CbGeAlD
Gefitinib—EGFR—liver—stomach cancer	0.000542	0.0107	CbGeAlD
Gefitinib—MKNK2—endocrine gland—stomach cancer	0.00053	0.0105	CbGeAlD
Gefitinib—STK10—lymphoid tissue—stomach cancer	0.000528	0.0104	CbGeAlD
Gefitinib—MKNK1—endocrine gland—stomach cancer	0.000523	0.0103	CbGeAlD
Gefitinib—STK10—digestive system—stomach cancer	0.000522	0.0103	CbGeAlD
Gefitinib—CSNK1E—liver—stomach cancer	0.000521	0.0103	CbGeAlD
Gefitinib—Bosutinib—FYN—stomach cancer	0.00052	0.104	CrCbGaD
Gefitinib—IRAK4—liver—stomach cancer	0.000513	0.0101	CbGeAlD
Gefitinib—ERBB3—liver—stomach cancer	0.000503	0.00993	CbGeAlD
Gefitinib—STK10—bone marrow—stomach cancer	0.000481	0.0095	CbGeAlD
Gefitinib—MKNK2—liver—stomach cancer	0.000478	0.00944	CbGeAlD
Gefitinib—IRAK1—liver—stomach cancer	0.000478	0.00944	CbGeAlD
Gefitinib—MKNK1—liver—stomach cancer	0.000472	0.00932	CbGeAlD
Gefitinib—Lapatinib—EGFR—stomach cancer	0.000458	0.0915	CrCbGaD
Gefitinib—STK10—endocrine gland—stomach cancer	0.000431	0.00851	CbGeAlD
Gefitinib—CHEK2—Doxorubicin—Epirubicin—stomach cancer	0.000418	0.204	CbGdCrCtD
Gefitinib—EGFR—lymph node—stomach cancer	0.000415	0.0082	CbGeAlD
Gefitinib—CSNK1E—lymph node—stomach cancer	0.000399	0.00789	CbGeAlD
Gefitinib—IRAK4—lymph node—stomach cancer	0.000393	0.00776	CbGeAlD
Gefitinib—STK10—liver—stomach cancer	0.000389	0.00768	CbGeAlD
Gefitinib—CHEK2—Epirubicin—Doxorubicin—stomach cancer	0.000387	0.188	CbGdCrCtD
Gefitinib—ERBB3—lymph node—stomach cancer	0.000385	0.00761	CbGeAlD
Gefitinib—MAP2K5—endocrine gland—stomach cancer	0.000385	0.0076	CbGeAlD
Gefitinib—CYP2C19—hematopoietic system—stomach cancer	0.000384	0.00758	CbGeAlD
Gefitinib—MKNK2—lymph node—stomach cancer	0.000366	0.00724	CbGeAlD
Gefitinib—IRAK1—lymph node—stomach cancer	0.000366	0.00724	CbGeAlD
Gefitinib—MKNK1—lymph node—stomach cancer	0.000362	0.00715	CbGeAlD
Gefitinib—Bosutinib—CHEK2—stomach cancer	0.000354	0.0706	CrCbGaD
Gefitinib—ORM1—bone marrow—stomach cancer	0.000349	0.00689	CbGeAlD
Gefitinib—MAP2K5—liver—stomach cancer	0.000347	0.00685	CbGeAlD
Gefitinib—Afatinib—EGFR—stomach cancer	0.000325	0.0648	CrCbGaD
Gefitinib—ORM1—endocrine gland—stomach cancer	0.000313	0.00617	CbGeAlD
Gefitinib—CYP1A1—hematopoietic system—stomach cancer	0.000309	0.00611	CbGeAlD
Gefitinib—CYP3A5—hematopoietic system—stomach cancer	0.000303	0.00597	CbGeAlD
Gefitinib—ABCB1—blood vessel—stomach cancer	0.000302	0.00596	CbGeAlD
Gefitinib—STK10—lymph node—stomach cancer	0.000298	0.00588	CbGeAlD
Gefitinib—CYP2C9—hematopoietic system—stomach cancer	0.000298	0.00588	CbGeAlD
Gefitinib—CYP1A1—epithelium—stomach cancer	0.000283	0.00558	CbGeAlD
Gefitinib—ORM1—liver—stomach cancer	0.000282	0.00556	CbGeAlD
Gefitinib—CYP2C19—digestive system—stomach cancer	0.000267	0.00527	CbGeAlD
Gefitinib—MAP2K5—lymph node—stomach cancer	0.000266	0.00525	CbGeAlD
Gefitinib—ALB—liver—stomach cancer	0.000247	0.00488	CbGeAlD
Gefitinib—CYP3A5—pancreas—stomach cancer	0.000246	0.00486	CbGeAlD
Gefitinib—Erlotinib—EGFR—stomach cancer	0.000229	0.0458	CrCbGaD
Gefitinib—CYP3A4—hematopoietic system—stomach cancer	0.000227	0.00448	CbGeAlD
Gefitinib—CYP2D6—hematopoietic system—stomach cancer	0.000223	0.00441	CbGeAlD
Gefitinib—CYP2C19—endocrine gland—stomach cancer	0.000221	0.00436	CbGeAlD
Gefitinib—ORM1—lymph node—stomach cancer	0.000216	0.00427	CbGeAlD
Gefitinib—CYP1A1—digestive system—stomach cancer	0.000215	0.00425	CbGeAlD
Gefitinib—CYP3A5—digestive system—stomach cancer	0.00021	0.00415	CbGeAlD
Gefitinib—ABCG2—bone marrow—stomach cancer	0.000209	0.00413	CbGeAlD
Gefitinib—CYP2C9—digestive system—stomach cancer	0.000207	0.00409	CbGeAlD
Gefitinib—CYP2C19—liver—stomach cancer	0.000199	0.00393	CbGeAlD
Gefitinib—ALB—lymph node—stomach cancer	0.000189	0.00374	CbGeAlD
Gefitinib—Vandetanib—VEGFA—stomach cancer	0.000179	0.0358	CrCbGaD
Gefitinib—CYP1A1—endocrine gland—stomach cancer	0.000178	0.00351	CbGeAlD
Gefitinib—Cisapride—CYP2A6—stomach cancer	0.000176	0.0352	CrCbGaD
Gefitinib—CYP3A5—endocrine gland—stomach cancer	0.000174	0.00343	CbGeAlD
Gefitinib—CYP2C9—endocrine gland—stomach cancer	0.000171	0.00338	CbGeAlD
Gefitinib—ABCG2—liver—stomach cancer	0.000169	0.00333	CbGeAlD
Gefitinib—ABCB1—hematopoietic system—stomach cancer	0.000161	0.00317	CbGeAlD
Gefitinib—CYP1A1—liver—stomach cancer	0.00016	0.00317	CbGeAlD
Gefitinib—CYP3A4—digestive system—stomach cancer	0.000158	0.00312	CbGeAlD
Gefitinib—CYP3A5—liver—stomach cancer	0.000157	0.0031	CbGeAlD
Gefitinib—CYP2D6—digestive system—stomach cancer	0.000155	0.00307	CbGeAlD
Gefitinib—CYP2C9—liver—stomach cancer	0.000154	0.00305	CbGeAlD
Gefitinib—Vandetanib—EGFR—stomach cancer	0.000151	0.0302	CrCbGaD
Gefitinib—ABCB1—epithelium—stomach cancer	0.000147	0.0029	CbGeAlD
Gefitinib—Iloperidone—HTR1A—stomach cancer	0.000142	0.0283	CrCbGaD
Gefitinib—Bosutinib—EGFR—stomach cancer	0.000141	0.0282	CrCbGaD
Gefitinib—ABCB1—pancreas—stomach cancer	0.000131	0.00258	CbGeAlD
Gefitinib—CYP3A4—endocrine gland—stomach cancer	0.00013	0.00258	CbGeAlD
Gefitinib—ABCG2—lymph node—stomach cancer	0.000129	0.00256	CbGeAlD
Gefitinib—CYP2D6—endocrine gland—stomach cancer	0.000128	0.00254	CbGeAlD
Gefitinib—CYP1A1—lymph node—stomach cancer	0.000123	0.00243	CbGeAlD
Gefitinib—CYP3A4—liver—stomach cancer	0.000118	0.00232	CbGeAlD
Gefitinib—CYP2D6—liver—stomach cancer	0.000116	0.00229	CbGeAlD
Gefitinib—ABCB1—lymphoid tissue—stomach cancer	0.000113	0.00223	CbGeAlD
Gefitinib—ABCB1—digestive system—stomach cancer	0.000112	0.00221	CbGeAlD
Gefitinib—Mediastinal disorder—Capecitabine—stomach cancer	0.000107	0.00102	CcSEcCtD
Gefitinib—Malnutrition—Docetaxel—stomach cancer	0.000107	0.00101	CcSEcCtD
Gefitinib—Arrhythmia—Capecitabine—stomach cancer	0.000106	0.00101	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Epirubicin—stomach cancer	0.000105	0.001	CcSEcCtD
Gefitinib—Decreased appetite—Fluorouracil—stomach cancer	0.000105	0.000997	CcSEcCtD
Gefitinib—Alopecia—Capecitabine—stomach cancer	0.000105	0.000997	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Fluorouracil—stomach cancer	0.000104	0.00099	CcSEcCtD
Gefitinib—Malnutrition—Capecitabine—stomach cancer	0.000103	0.000982	CcSEcCtD
Gefitinib—Pain—Fluorouracil—stomach cancer	0.000103	0.000981	CcSEcCtD
Gefitinib—Gastrointestinal pain—Irinotecan—stomach cancer	0.000103	0.000979	CcSEcCtD
Gefitinib—ABCB1—bone marrow—stomach cancer	0.000103	0.00203	CbGeAlD
Gefitinib—Dehydration—Doxorubicin—stomach cancer	0.000103	0.000978	CcSEcCtD
Gefitinib—Dry skin—Doxorubicin—stomach cancer	0.000101	0.000964	CcSEcCtD
Gefitinib—Pancreatitis—Epirubicin—stomach cancer	0.000101	0.000963	CcSEcCtD
Gefitinib—Hypokalaemia—Doxorubicin—stomach cancer	0.000101	0.000957	CcSEcCtD
Gefitinib—Body temperature increased—Irinotecan—stomach cancer	9.97e-05	0.000947	CcSEcCtD
Gefitinib—Abdominal pain—Irinotecan—stomach cancer	9.97e-05	0.000947	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Doxorubicin—stomach cancer	9.96e-05	0.000947	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Doxorubicin—stomach cancer	9.96e-05	0.000947	CcSEcCtD
Gefitinib—Pneumonia—Methotrexate—stomach cancer	9.9e-05	0.000941	CcSEcCtD
Gefitinib—Anaemia—Docetaxel—stomach cancer	9.87e-05	0.000938	CcSEcCtD
Gefitinib—Infestation NOS—Methotrexate—stomach cancer	9.85e-05	0.000936	CcSEcCtD
Gefitinib—Infestation—Methotrexate—stomach cancer	9.85e-05	0.000936	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Methotrexate—stomach cancer	9.76e-05	0.000928	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Doxorubicin—stomach cancer	9.76e-05	0.000927	CcSEcCtD
Gefitinib—Stomatitis—Methotrexate—stomach cancer	9.6e-05	0.000912	CcSEcCtD
Gefitinib—Urticaria—Fluorouracil—stomach cancer	9.59e-05	0.000911	CcSEcCtD
Gefitinib—Conjunctivitis—Methotrexate—stomach cancer	9.57e-05	0.000909	CcSEcCtD
Gefitinib—Anaemia—Capecitabine—stomach cancer	9.55e-05	0.000908	CcSEcCtD
Gefitinib—Body temperature increased—Fluorouracil—stomach cancer	9.54e-05	0.000907	CcSEcCtD
Gefitinib—Haematuria—Methotrexate—stomach cancer	9.39e-05	0.000892	CcSEcCtD
Gefitinib—Pancreatitis—Doxorubicin—stomach cancer	9.38e-05	0.000891	CcSEcCtD
Gefitinib—Weight decreased—Epirubicin—stomach cancer	9.35e-05	0.000888	CcSEcCtD
Gefitinib—Malaise—Capecitabine—stomach cancer	9.32e-05	0.000886	CcSEcCtD
Gefitinib—Cough—Docetaxel—stomach cancer	9.32e-05	0.000885	CcSEcCtD
Gefitinib—Hepatobiliary disease—Methotrexate—stomach cancer	9.31e-05	0.000885	CcSEcCtD
Gefitinib—Epistaxis—Methotrexate—stomach cancer	9.29e-05	0.000883	CcSEcCtD
Gefitinib—Hypersensitivity—Irinotecan—stomach cancer	9.29e-05	0.000882	CcSEcCtD
Gefitinib—Pneumonia—Epirubicin—stomach cancer	9.27e-05	0.000881	CcSEcCtD
Gefitinib—ABCB1—endocrine gland—stomach cancer	9.23e-05	0.00182	CbGeAlD
Gefitinib—Infestation NOS—Epirubicin—stomach cancer	9.22e-05	0.000876	CcSEcCtD
Gefitinib—Infestation—Epirubicin—stomach cancer	9.22e-05	0.000876	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Epirubicin—stomach cancer	9.14e-05	0.000868	CcSEcCtD
Gefitinib—Asthenia—Irinotecan—stomach cancer	9.04e-05	0.000859	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—stomach cancer	9.03e-05	0.000858	CcSEcCtD
Gefitinib—Cough—Capecitabine—stomach cancer	9.02e-05	0.000857	CcSEcCtD
Gefitinib—Stomatitis—Epirubicin—stomach cancer	8.98e-05	0.000853	CcSEcCtD
Gefitinib—Conjunctivitis—Epirubicin—stomach cancer	8.96e-05	0.000851	CcSEcCtD
Gefitinib—Hypersensitivity—Fluorouracil—stomach cancer	8.9e-05	0.000845	CcSEcCtD
Gefitinib—Dry mouth—Docetaxel—stomach cancer	8.89e-05	0.000845	CcSEcCtD
Gefitinib—Haemoglobin—Methotrexate—stomach cancer	8.89e-05	0.000844	CcSEcCtD
Gefitinib—Haemorrhage—Methotrexate—stomach cancer	8.84e-05	0.00084	CcSEcCtD
Gefitinib—Hepatitis—Methotrexate—stomach cancer	8.84e-05	0.00084	CcSEcCtD
Gefitinib—Haematuria—Epirubicin—stomach cancer	8.79e-05	0.000835	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—stomach cancer	8.74e-05	0.00083	CcSEcCtD
Gefitinib—Urinary tract disorder—Methotrexate—stomach cancer	8.73e-05	0.000829	CcSEcCtD
Gefitinib—Hepatobiliary disease—Epirubicin—stomach cancer	8.72e-05	0.000828	CcSEcCtD
Gefitinib—Epistaxis—Epirubicin—stomach cancer	8.69e-05	0.000826	CcSEcCtD
Gefitinib—Urethral disorder—Methotrexate—stomach cancer	8.67e-05	0.000823	CcSEcCtD
Gefitinib—Infection—Docetaxel—stomach cancer	8.66e-05	0.000823	CcSEcCtD
Gefitinib—Weight decreased—Doxorubicin—stomach cancer	8.65e-05	0.000822	CcSEcCtD
Gefitinib—Diarrhoea—Irinotecan—stomach cancer	8.63e-05	0.000819	CcSEcCtD
Gefitinib—Dry mouth—Capecitabine—stomach cancer	8.61e-05	0.000818	CcSEcCtD
Gefitinib—Pneumonia—Doxorubicin—stomach cancer	8.58e-05	0.000815	CcSEcCtD
Gefitinib—Shock—Docetaxel—stomach cancer	8.57e-05	0.000815	CcSEcCtD
Gefitinib—Nervous system disorder—Docetaxel—stomach cancer	8.55e-05	0.000812	CcSEcCtD
Gefitinib—Pruritus—Fluorouracil—stomach cancer	8.54e-05	0.000812	CcSEcCtD
Gefitinib—Thrombocytopenia—Docetaxel—stomach cancer	8.53e-05	0.000811	CcSEcCtD
Gefitinib—Infestation—Doxorubicin—stomach cancer	8.53e-05	0.00081	CcSEcCtD
Gefitinib—Infestation NOS—Doxorubicin—stomach cancer	8.53e-05	0.00081	CcSEcCtD
Gefitinib—Skin disorder—Docetaxel—stomach cancer	8.46e-05	0.000804	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Doxorubicin—stomach cancer	8.45e-05	0.000803	CcSEcCtD
Gefitinib—Infection—Capecitabine—stomach cancer	8.38e-05	0.000796	CcSEcCtD
Gefitinib—Erythema multiforme—Methotrexate—stomach cancer	8.36e-05	0.000794	CcSEcCtD
Gefitinib—ABCB1—liver—stomach cancer	8.33e-05	0.00164	CbGeAlD
Gefitinib—Haemoglobin—Epirubicin—stomach cancer	8.32e-05	0.00079	CcSEcCtD
Gefitinib—Stomatitis—Doxorubicin—stomach cancer	8.31e-05	0.00079	CcSEcCtD
Gefitinib—Anorexia—Docetaxel—stomach cancer	8.31e-05	0.000789	CcSEcCtD
Gefitinib—Shock—Capecitabine—stomach cancer	8.3e-05	0.000789	CcSEcCtD
Gefitinib—Conjunctivitis—Doxorubicin—stomach cancer	8.29e-05	0.000788	CcSEcCtD
Gefitinib—Nervous system disorder—Capecitabine—stomach cancer	8.27e-05	0.000786	CcSEcCtD
Gefitinib—Hepatitis—Epirubicin—stomach cancer	8.27e-05	0.000786	CcSEcCtD
Gefitinib—Haemorrhage—Epirubicin—stomach cancer	8.27e-05	0.000786	CcSEcCtD
Gefitinib—Eye disorder—Methotrexate—stomach cancer	8.26e-05	0.000785	CcSEcCtD
Gefitinib—Diarrhoea—Fluorouracil—stomach cancer	8.26e-05	0.000785	CcSEcCtD
Gefitinib—Thrombocytopenia—Capecitabine—stomach cancer	8.26e-05	0.000785	CcSEcCtD
Gefitinib—Cardiac disorder—Methotrexate—stomach cancer	8.2e-05	0.00078	CcSEcCtD
Gefitinib—Skin disorder—Capecitabine—stomach cancer	8.19e-05	0.000779	CcSEcCtD
Gefitinib—Urinary tract disorder—Epirubicin—stomach cancer	8.17e-05	0.000776	CcSEcCtD
Gefitinib—Oedema peripheral—Epirubicin—stomach cancer	8.15e-05	0.000774	CcSEcCtD
Gefitinib—Hypotension—Docetaxel—stomach cancer	8.14e-05	0.000774	CcSEcCtD
Gefitinib—Haematuria—Doxorubicin—stomach cancer	8.13e-05	0.000772	CcSEcCtD
Gefitinib—Urethral disorder—Epirubicin—stomach cancer	8.11e-05	0.000771	CcSEcCtD
Gefitinib—Hepatobiliary disease—Doxorubicin—stomach cancer	8.06e-05	0.000766	CcSEcCtD
Gefitinib—Epistaxis—Doxorubicin—stomach cancer	8.04e-05	0.000764	CcSEcCtD
Gefitinib—Anorexia—Capecitabine—stomach cancer	8.04e-05	0.000764	CcSEcCtD
Gefitinib—Angiopathy—Methotrexate—stomach cancer	8.02e-05	0.000762	CcSEcCtD
Gefitinib—Vomiting—Irinotecan—stomach cancer	8.01e-05	0.000762	CcSEcCtD
Gefitinib—Mediastinal disorder—Methotrexate—stomach cancer	7.97e-05	0.000757	CcSEcCtD
Gefitinib—Rash—Irinotecan—stomach cancer	7.95e-05	0.000755	CcSEcCtD
Gefitinib—Dermatitis—Irinotecan—stomach cancer	7.94e-05	0.000754	CcSEcCtD
Gefitinib—Hypotension—Capecitabine—stomach cancer	7.88e-05	0.000749	CcSEcCtD
Gefitinib—Erythema multiforme—Epirubicin—stomach cancer	7.82e-05	0.000743	CcSEcCtD
Gefitinib—Alopecia—Methotrexate—stomach cancer	7.81e-05	0.000742	CcSEcCtD
Gefitinib—Dyspnoea—Docetaxel—stomach cancer	7.77e-05	0.000738	CcSEcCtD
Gefitinib—Eye disorder—Epirubicin—stomach cancer	7.73e-05	0.000735	CcSEcCtD
Gefitinib—Malnutrition—Methotrexate—stomach cancer	7.7e-05	0.000731	CcSEcCtD
Gefitinib—Haemoglobin—Doxorubicin—stomach cancer	7.69e-05	0.000731	CcSEcCtD
Gefitinib—Cardiac disorder—Epirubicin—stomach cancer	7.68e-05	0.000729	CcSEcCtD
Gefitinib—Vomiting—Fluorouracil—stomach cancer	7.68e-05	0.000729	CcSEcCtD
Gefitinib—Haemorrhage—Doxorubicin—stomach cancer	7.65e-05	0.000727	CcSEcCtD
Gefitinib—Hepatitis—Doxorubicin—stomach cancer	7.65e-05	0.000727	CcSEcCtD
Gefitinib—Rash—Fluorouracil—stomach cancer	7.61e-05	0.000723	CcSEcCtD
Gefitinib—Dermatitis—Fluorouracil—stomach cancer	7.61e-05	0.000723	CcSEcCtD
Gefitinib—Decreased appetite—Docetaxel—stomach cancer	7.58e-05	0.00072	CcSEcCtD
Gefitinib—Urinary tract disorder—Doxorubicin—stomach cancer	7.56e-05	0.000718	CcSEcCtD
Gefitinib—Oedema peripheral—Doxorubicin—stomach cancer	7.54e-05	0.000716	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Docetaxel—stomach cancer	7.52e-05	0.000715	CcSEcCtD
Gefitinib—Dyspnoea—Capecitabine—stomach cancer	7.52e-05	0.000715	CcSEcCtD
Gefitinib—Fatigue—Docetaxel—stomach cancer	7.51e-05	0.000714	CcSEcCtD
Gefitinib—Angiopathy—Epirubicin—stomach cancer	7.51e-05	0.000713	CcSEcCtD
Gefitinib—Urethral disorder—Doxorubicin—stomach cancer	7.5e-05	0.000713	CcSEcCtD
Gefitinib—Nausea—Irinotecan—stomach cancer	7.49e-05	0.000711	CcSEcCtD
Gefitinib—Mediastinal disorder—Epirubicin—stomach cancer	7.46e-05	0.000708	CcSEcCtD
Gefitinib—Constipation—Docetaxel—stomach cancer	7.45e-05	0.000708	CcSEcCtD
Gefitinib—Pain—Docetaxel—stomach cancer	7.45e-05	0.000708	CcSEcCtD
Gefitinib—Arrhythmia—Epirubicin—stomach cancer	7.39e-05	0.000702	CcSEcCtD
Gefitinib—Decreased appetite—Capecitabine—stomach cancer	7.33e-05	0.000697	CcSEcCtD
Gefitinib—Alopecia—Epirubicin—stomach cancer	7.31e-05	0.000695	CcSEcCtD
Gefitinib—Erlotinib—ALB—stomach cancer	7.31e-05	0.0146	CrCbGaD
Gefitinib—Gastrointestinal disorder—Capecitabine—stomach cancer	7.28e-05	0.000692	CcSEcCtD
Gefitinib—Fatigue—Capecitabine—stomach cancer	7.27e-05	0.000691	CcSEcCtD
Gefitinib—Erythema multiforme—Doxorubicin—stomach cancer	7.24e-05	0.000688	CcSEcCtD
Gefitinib—Constipation—Capecitabine—stomach cancer	7.21e-05	0.000685	CcSEcCtD
Gefitinib—Pain—Capecitabine—stomach cancer	7.21e-05	0.000685	CcSEcCtD
Gefitinib—Malnutrition—Epirubicin—stomach cancer	7.2e-05	0.000684	CcSEcCtD
Gefitinib—Nausea—Fluorouracil—stomach cancer	7.17e-05	0.000681	CcSEcCtD
Gefitinib—Eye disorder—Doxorubicin—stomach cancer	7.15e-05	0.00068	CcSEcCtD
Gefitinib—Gastrointestinal pain—Docetaxel—stomach cancer	7.13e-05	0.000677	CcSEcCtD
Gefitinib—Anaemia—Methotrexate—stomach cancer	7.11e-05	0.000676	CcSEcCtD
Gefitinib—Cardiac disorder—Doxorubicin—stomach cancer	7.1e-05	0.000675	CcSEcCtD
Gefitinib—Angiopathy—Doxorubicin—stomach cancer	6.95e-05	0.00066	CcSEcCtD
Gefitinib—Malaise—Methotrexate—stomach cancer	6.94e-05	0.000659	CcSEcCtD
Gefitinib—Gastrointestinal pain—Capecitabine—stomach cancer	6.9e-05	0.000655	CcSEcCtD
Gefitinib—Mediastinal disorder—Doxorubicin—stomach cancer	6.9e-05	0.000655	CcSEcCtD
Gefitinib—Abdominal pain—Docetaxel—stomach cancer	6.89e-05	0.000655	CcSEcCtD
Gefitinib—Body temperature increased—Docetaxel—stomach cancer	6.89e-05	0.000655	CcSEcCtD
Gefitinib—Arrhythmia—Doxorubicin—stomach cancer	6.84e-05	0.00065	CcSEcCtD
Gefitinib—Alopecia—Doxorubicin—stomach cancer	6.76e-05	0.000643	CcSEcCtD
Gefitinib—Cough—Methotrexate—stomach cancer	6.72e-05	0.000638	CcSEcCtD
Gefitinib—Urticaria—Capecitabine—stomach cancer	6.7e-05	0.000637	CcSEcCtD
Gefitinib—Abdominal pain—Capecitabine—stomach cancer	6.67e-05	0.000634	CcSEcCtD
Gefitinib—Body temperature increased—Capecitabine—stomach cancer	6.67e-05	0.000634	CcSEcCtD
Gefitinib—Malnutrition—Doxorubicin—stomach cancer	6.66e-05	0.000633	CcSEcCtD
Gefitinib—Anaemia—Epirubicin—stomach cancer	6.66e-05	0.000632	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	6.51e-05	0.000618	CcSEcCtD
Gefitinib—Malaise—Epirubicin—stomach cancer	6.49e-05	0.000617	CcSEcCtD
Gefitinib—Hypersensitivity—Docetaxel—stomach cancer	6.42e-05	0.00061	CcSEcCtD
Gefitinib—ABCB1—lymph node—stomach cancer	6.38e-05	0.00126	CbGeAlD
Gefitinib—Cough—Epirubicin—stomach cancer	6.28e-05	0.000597	CcSEcCtD
Gefitinib—Asthenia—Docetaxel—stomach cancer	6.25e-05	0.000594	CcSEcCtD
Gefitinib—Infection—Methotrexate—stomach cancer	6.24e-05	0.000593	CcSEcCtD
Gefitinib—Hypersensitivity—Capecitabine—stomach cancer	6.22e-05	0.000591	CcSEcCtD
Gefitinib—Pruritus—Docetaxel—stomach cancer	6.17e-05	0.000586	CcSEcCtD
Gefitinib—Nervous system disorder—Methotrexate—stomach cancer	6.16e-05	0.000585	CcSEcCtD
Gefitinib—Anaemia—Doxorubicin—stomach cancer	6.16e-05	0.000585	CcSEcCtD
Gefitinib—Thrombocytopenia—Methotrexate—stomach cancer	6.15e-05	0.000584	CcSEcCtD
Gefitinib—Skin disorder—Methotrexate—stomach cancer	6.1e-05	0.00058	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	6.09e-05	0.000579	CcSEcCtD
Gefitinib—Asthenia—Capecitabine—stomach cancer	6.05e-05	0.000575	CcSEcCtD
Gefitinib—Malaise—Doxorubicin—stomach cancer	6.01e-05	0.000571	CcSEcCtD
Gefitinib—Dry mouth—Epirubicin—stomach cancer	6e-05	0.00057	CcSEcCtD
Gefitinib—Anorexia—Methotrexate—stomach cancer	5.99e-05	0.000569	CcSEcCtD
Gefitinib—Pruritus—Capecitabine—stomach cancer	5.97e-05	0.000567	CcSEcCtD
Gefitinib—Diarrhoea—Docetaxel—stomach cancer	5.96e-05	0.000566	CcSEcCtD
Gefitinib—Hypotension—Methotrexate—stomach cancer	5.87e-05	0.000558	CcSEcCtD
Gefitinib—Infection—Epirubicin—stomach cancer	5.84e-05	0.000555	CcSEcCtD
Gefitinib—Cough—Doxorubicin—stomach cancer	5.81e-05	0.000552	CcSEcCtD
Gefitinib—Shock—Epirubicin—stomach cancer	5.78e-05	0.000549	CcSEcCtD
Gefitinib—Diarrhoea—Capecitabine—stomach cancer	5.77e-05	0.000548	CcSEcCtD
Gefitinib—Nervous system disorder—Epirubicin—stomach cancer	5.76e-05	0.000548	CcSEcCtD
Gefitinib—Thrombocytopenia—Epirubicin—stomach cancer	5.75e-05	0.000547	CcSEcCtD
Gefitinib—Skin disorder—Epirubicin—stomach cancer	5.71e-05	0.000542	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	5.63e-05	0.000535	CcSEcCtD
Gefitinib—Anorexia—Epirubicin—stomach cancer	5.6e-05	0.000532	CcSEcCtD
Gefitinib—Dyspnoea—Methotrexate—stomach cancer	5.6e-05	0.000532	CcSEcCtD
Gefitinib—Dry mouth—Doxorubicin—stomach cancer	5.55e-05	0.000527	CcSEcCtD
Gefitinib—Vomiting—Docetaxel—stomach cancer	5.54e-05	0.000526	CcSEcCtD
Gefitinib—Rash—Docetaxel—stomach cancer	5.49e-05	0.000522	CcSEcCtD
Gefitinib—Hypotension—Epirubicin—stomach cancer	5.49e-05	0.000522	CcSEcCtD
Gefitinib—Dermatitis—Docetaxel—stomach cancer	5.49e-05	0.000522	CcSEcCtD
Gefitinib—Decreased appetite—Methotrexate—stomach cancer	5.46e-05	0.000519	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Methotrexate—stomach cancer	5.42e-05	0.000515	CcSEcCtD
Gefitinib—Fatigue—Methotrexate—stomach cancer	5.41e-05	0.000514	CcSEcCtD
Gefitinib—Infection—Doxorubicin—stomach cancer	5.4e-05	0.000513	CcSEcCtD
Gefitinib—Pain—Methotrexate—stomach cancer	5.37e-05	0.00051	CcSEcCtD
Gefitinib—Vomiting—Capecitabine—stomach cancer	5.36e-05	0.00051	CcSEcCtD
Gefitinib—Shock—Doxorubicin—stomach cancer	5.35e-05	0.000508	CcSEcCtD
Gefitinib—Nervous system disorder—Doxorubicin—stomach cancer	5.33e-05	0.000507	CcSEcCtD
Gefitinib—Thrombocytopenia—Doxorubicin—stomach cancer	5.32e-05	0.000506	CcSEcCtD
Gefitinib—Rash—Capecitabine—stomach cancer	5.32e-05	0.000505	CcSEcCtD
Gefitinib—Dermatitis—Capecitabine—stomach cancer	5.31e-05	0.000505	CcSEcCtD
Gefitinib—Skin disorder—Doxorubicin—stomach cancer	5.28e-05	0.000502	CcSEcCtD
Gefitinib—Dyspnoea—Epirubicin—stomach cancer	5.24e-05	0.000498	CcSEcCtD
Gefitinib—Anorexia—Doxorubicin—stomach cancer	5.18e-05	0.000493	CcSEcCtD
Gefitinib—Nausea—Docetaxel—stomach cancer	5.18e-05	0.000492	CcSEcCtD
Gefitinib—Gastrointestinal pain—Methotrexate—stomach cancer	5.14e-05	0.000488	CcSEcCtD
Gefitinib—Decreased appetite—Epirubicin—stomach cancer	5.11e-05	0.000485	CcSEcCtD
Gefitinib—Hypotension—Doxorubicin—stomach cancer	5.08e-05	0.000483	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Epirubicin—stomach cancer	5.07e-05	0.000482	CcSEcCtD
Gefitinib—Fatigue—Epirubicin—stomach cancer	5.07e-05	0.000481	CcSEcCtD
Gefitinib—Pain—Epirubicin—stomach cancer	5.03e-05	0.000478	CcSEcCtD
Gefitinib—Constipation—Epirubicin—stomach cancer	5.03e-05	0.000478	CcSEcCtD
Gefitinib—Nausea—Capecitabine—stomach cancer	5.01e-05	0.000476	CcSEcCtD
Gefitinib—Urticaria—Methotrexate—stomach cancer	4.99e-05	0.000474	CcSEcCtD
Gefitinib—Abdominal pain—Methotrexate—stomach cancer	4.96e-05	0.000472	CcSEcCtD
Gefitinib—Body temperature increased—Methotrexate—stomach cancer	4.96e-05	0.000472	CcSEcCtD
Gefitinib—Dyspnoea—Doxorubicin—stomach cancer	4.85e-05	0.000461	CcSEcCtD
Gefitinib—Vandetanib—ALB—stomach cancer	4.81e-05	0.00961	CrCbGaD
Gefitinib—Gastrointestinal pain—Epirubicin—stomach cancer	4.81e-05	0.000457	CcSEcCtD
Gefitinib—Decreased appetite—Doxorubicin—stomach cancer	4.73e-05	0.000449	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Doxorubicin—stomach cancer	4.7e-05	0.000446	CcSEcCtD
Gefitinib—Fatigue—Doxorubicin—stomach cancer	4.69e-05	0.000445	CcSEcCtD
Gefitinib—Urticaria—Epirubicin—stomach cancer	4.67e-05	0.000444	CcSEcCtD
Gefitinib—Pain—Doxorubicin—stomach cancer	4.65e-05	0.000442	CcSEcCtD
Gefitinib—Constipation—Doxorubicin—stomach cancer	4.65e-05	0.000442	CcSEcCtD
Gefitinib—Abdominal pain—Epirubicin—stomach cancer	4.65e-05	0.000441	CcSEcCtD
Gefitinib—Body temperature increased—Epirubicin—stomach cancer	4.65e-05	0.000441	CcSEcCtD
Gefitinib—Hypersensitivity—Methotrexate—stomach cancer	4.63e-05	0.00044	CcSEcCtD
Gefitinib—Asthenia—Methotrexate—stomach cancer	4.51e-05	0.000428	CcSEcCtD
Gefitinib—Gastrointestinal pain—Doxorubicin—stomach cancer	4.45e-05	0.000423	CcSEcCtD
Gefitinib—Pruritus—Methotrexate—stomach cancer	4.44e-05	0.000422	CcSEcCtD
Gefitinib—Hypersensitivity—Epirubicin—stomach cancer	4.33e-05	0.000411	CcSEcCtD
Gefitinib—Urticaria—Doxorubicin—stomach cancer	4.32e-05	0.00041	CcSEcCtD
Gefitinib—Abdominal pain—Doxorubicin—stomach cancer	4.3e-05	0.000408	CcSEcCtD
Gefitinib—Body temperature increased—Doxorubicin—stomach cancer	4.3e-05	0.000408	CcSEcCtD
Gefitinib—Diarrhoea—Methotrexate—stomach cancer	4.3e-05	0.000408	CcSEcCtD
Gefitinib—Asthenia—Epirubicin—stomach cancer	4.22e-05	0.000401	CcSEcCtD
Gefitinib—Pruritus—Epirubicin—stomach cancer	4.16e-05	0.000395	CcSEcCtD
Gefitinib—Diarrhoea—Epirubicin—stomach cancer	4.02e-05	0.000382	CcSEcCtD
Gefitinib—Hypersensitivity—Doxorubicin—stomach cancer	4.01e-05	0.000381	CcSEcCtD
Gefitinib—Vomiting—Methotrexate—stomach cancer	3.99e-05	0.000379	CcSEcCtD
Gefitinib—Rash—Methotrexate—stomach cancer	3.96e-05	0.000376	CcSEcCtD
Gefitinib—Dermatitis—Methotrexate—stomach cancer	3.96e-05	0.000376	CcSEcCtD
Gefitinib—Asthenia—Doxorubicin—stomach cancer	3.9e-05	0.000371	CcSEcCtD
Gefitinib—Pruritus—Doxorubicin—stomach cancer	3.85e-05	0.000366	CcSEcCtD
Gefitinib—Vomiting—Epirubicin—stomach cancer	3.74e-05	0.000355	CcSEcCtD
Gefitinib—Nausea—Methotrexate—stomach cancer	3.73e-05	0.000354	CcSEcCtD
Gefitinib—Diarrhoea—Doxorubicin—stomach cancer	3.72e-05	0.000354	CcSEcCtD
Gefitinib—Rash—Epirubicin—stomach cancer	3.71e-05	0.000352	CcSEcCtD
Gefitinib—Dermatitis—Epirubicin—stomach cancer	3.7e-05	0.000352	CcSEcCtD
Gefitinib—Nausea—Epirubicin—stomach cancer	3.49e-05	0.000332	CcSEcCtD
Gefitinib—Vomiting—Doxorubicin—stomach cancer	3.46e-05	0.000329	CcSEcCtD
Gefitinib—Rash—Doxorubicin—stomach cancer	3.43e-05	0.000326	CcSEcCtD
Gefitinib—Dermatitis—Doxorubicin—stomach cancer	3.43e-05	0.000325	CcSEcCtD
Gefitinib—Nausea—Doxorubicin—stomach cancer	3.23e-05	0.000307	CcSEcCtD
Gefitinib—ABCB1—Transmembrane transport of small molecules—ALB—stomach cancer	2.31e-06	2.05e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ENO1—stomach cancer	2.31e-06	2.05e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—VEGFA—stomach cancer	2.3e-06	2.05e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CDKN1B—stomach cancer	2.3e-06	2.04e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—ERBB2—stomach cancer	2.29e-06	2.04e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—HRAS—stomach cancer	2.29e-06	2.04e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GSTP1—stomach cancer	2.29e-06	2.03e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—STAT3—stomach cancer	2.28e-06	2.03e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HRAS—stomach cancer	2.27e-06	2.02e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—PIK3CA—stomach cancer	2.27e-06	2.02e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CXCL8—stomach cancer	2.27e-06	2.02e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—stomach cancer	2.27e-06	2.02e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—IL6—stomach cancer	2.27e-06	2.02e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CAV1—stomach cancer	2.27e-06	2.02e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—APOA1—stomach cancer	2.26e-06	2.01e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL1B—stomach cancer	2.26e-06	2.01e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—HMOX1—stomach cancer	2.25e-06	2.01e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—TYMS—stomach cancer	2.25e-06	2e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CD44—stomach cancer	2.24e-06	2e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PTGS2—stomach cancer	2.24e-06	1.99e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—PIK3CA—stomach cancer	2.23e-06	1.98e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PPARG—stomach cancer	2.22e-06	1.98e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—GSTM1—stomach cancer	2.22e-06	1.98e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CDKN1B—stomach cancer	2.22e-06	1.98e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—VEGFA—stomach cancer	2.22e-06	1.97e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TP53—stomach cancer	2.2e-06	1.96e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—STAT3—stomach cancer	2.2e-06	1.95e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—IL6—stomach cancer	2.19e-06	1.95e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CD44—stomach cancer	2.19e-06	1.95e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—JUN—stomach cancer	2.19e-06	1.95e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	2.18e-06	1.94e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MAPK3—stomach cancer	2.18e-06	1.94e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SREBF2—stomach cancer	2.17e-06	1.93e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PRKCB—stomach cancer	2.16e-06	1.92e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL6ST—stomach cancer	2.15e-06	1.91e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—RORA—stomach cancer	2.14e-06	1.91e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—TYMS—stomach cancer	2.13e-06	1.89e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PPP2R1A—stomach cancer	2.12e-06	1.89e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—CDKN1B—stomach cancer	2.12e-06	1.89e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CDKN1A—stomach cancer	2.12e-06	1.89e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CCND1—stomach cancer	2.12e-06	1.88e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MYC—stomach cancer	2.12e-06	1.88e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—JUN—stomach cancer	2.11e-06	1.88e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—HRAS—stomach cancer	2.1e-06	1.87e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GSTM1—stomach cancer	2.1e-06	1.87e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MAPK3—stomach cancer	2.1e-06	1.87e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—VEGFA—stomach cancer	2.1e-06	1.87e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ERCC2—stomach cancer	2.09e-06	1.86e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GSTP1—stomach cancer	2.08e-06	1.85e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MAPK1—stomach cancer	2.07e-06	1.84e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—EGFR—stomach cancer	2.07e-06	1.84e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—MAPK8—stomach cancer	2.07e-06	1.84e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—APC—stomach cancer	2.06e-06	1.84e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HRAS—stomach cancer	2.06e-06	1.84e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CD44—stomach cancer	2.06e-06	1.84e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MMP9—stomach cancer	2.06e-06	1.83e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—HMOX1—stomach cancer	2.06e-06	1.83e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CDKN1A—stomach cancer	2.05e-06	1.82e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CD44—stomach cancer	2.05e-06	1.82e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MYC—stomach cancer	2.04e-06	1.82e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IL6—stomach cancer	2.01e-06	1.79e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALDOB—stomach cancer	2.01e-06	1.79e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—ALB—stomach cancer	2e-06	1.78e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MAPK8—stomach cancer	2e-06	1.78e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MAPK1—stomach cancer	2e-06	1.78e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—EGFR—stomach cancer	2e-06	1.78e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	1.98e-06	1.77e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—MAPK3—stomach cancer	1.98e-06	1.77e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—MAPK3—stomach cancer	1.98e-06	1.76e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ERCC2—stomach cancer	1.98e-06	1.76e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL6—stomach cancer	1.97e-06	1.76e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—MTHFR—stomach cancer	1.97e-06	1.75e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—CDKN1A—stomach cancer	1.96e-06	1.74e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—KRAS—stomach cancer	1.96e-06	1.74e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—TYMS—stomach cancer	1.94e-06	1.72e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL6R—stomach cancer	1.92e-06	1.71e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GSTM1—stomach cancer	1.92e-06	1.7e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—NOS3—stomach cancer	1.91e-06	1.7e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PPP2R1A—stomach cancer	1.91e-06	1.7e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—STAT3—stomach cancer	1.89e-06	1.68e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—MAPK1—stomach cancer	1.89e-06	1.68e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—KRAS—stomach cancer	1.89e-06	1.68e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—MAPK1—stomach cancer	1.88e-06	1.67e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GSTP1—stomach cancer	1.87e-06	1.67e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALOX5—stomach cancer	1.87e-06	1.66e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PPP2R1A—stomach cancer	1.86e-06	1.66e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—MTHFR—stomach cancer	1.86e-06	1.65e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—VEGFA—stomach cancer	1.85e-06	1.64e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—HMOX1—stomach cancer	1.85e-06	1.64e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—DPYD—stomach cancer	1.84e-06	1.63e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—STAT3—stomach cancer	1.83e-06	1.63e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GSTP1—stomach cancer	1.83e-06	1.63e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CAV1—stomach cancer	1.81e-06	1.61e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—APOA1—stomach cancer	1.81e-06	1.61e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—MAPK3—stomach cancer	1.81e-06	1.61e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—HMOX1—stomach cancer	1.8e-06	1.6e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ERCC2—stomach cancer	1.8e-06	1.6e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—PIK3CA—stomach cancer	1.8e-06	1.6e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SERPINE1—stomach cancer	1.79e-06	1.6e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—KRAS—stomach cancer	1.78e-06	1.59e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—KRAS—stomach cancer	1.78e-06	1.58e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PPP2R1A—stomach cancer	1.75e-06	1.56e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTGS2—stomach cancer	1.75e-06	1.56e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MAPK3—stomach cancer	1.75e-06	1.55e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—STAT3—stomach cancer	1.75e-06	1.55e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—TYMS—stomach cancer	1.74e-06	1.55e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PPP2R1A—stomach cancer	1.74e-06	1.55e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—stomach cancer	1.74e-06	1.55e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—PIK3CA—stomach cancer	1.73e-06	1.54e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—RHOA—stomach cancer	1.73e-06	1.54e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSTP1—stomach cancer	1.72e-06	1.53e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GSTM1—stomach cancer	1.72e-06	1.53e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—MAPK1—stomach cancer	1.72e-06	1.53e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NOS3—stomach cancer	1.71e-06	1.52e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CAV1—stomach cancer	1.71e-06	1.52e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—APOA1—stomach cancer	1.71e-06	1.52e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTP1—stomach cancer	1.71e-06	1.52e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MYC—stomach cancer	1.7e-06	1.51e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—TYMS—stomach cancer	1.7e-06	1.51e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—HMOX1—stomach cancer	1.7e-06	1.51e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—MTHFR—stomach cancer	1.69e-06	1.51e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—HMOX1—stomach cancer	1.68e-06	1.5e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GSTM1—stomach cancer	1.68e-06	1.49e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—stomach cancer	1.68e-06	1.49e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MAPK3—stomach cancer	1.67e-06	1.48e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—HRAS—stomach cancer	1.66e-06	1.48e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MAPK1—stomach cancer	1.66e-06	1.48e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EGFR—stomach cancer	1.66e-06	1.48e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—PIK3CA—stomach cancer	1.64e-06	1.46e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	1.64e-06	1.46e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—PIK3CA—stomach cancer	1.63e-06	1.45e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—KRAS—stomach cancer	1.62e-06	1.44e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTT1—stomach cancer	1.62e-06	1.44e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MYC—stomach cancer	1.62e-06	1.44e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ERCC2—stomach cancer	1.62e-06	1.44e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP2A6—stomach cancer	1.6e-06	1.43e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ERBB2—stomach cancer	1.6e-06	1.43e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—HRAS—stomach cancer	1.6e-06	1.43e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—TYMS—stomach cancer	1.6e-06	1.42e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PPARG—stomach cancer	1.59e-06	1.42e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL6—stomach cancer	1.59e-06	1.42e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MAPK1—stomach cancer	1.59e-06	1.41e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—TYMS—stomach cancer	1.59e-06	1.41e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—stomach cancer	1.58e-06	1.41e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSTM1—stomach cancer	1.58e-06	1.41e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ERCC2—stomach cancer	1.58e-06	1.4e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—KRAS—stomach cancer	1.57e-06	1.4e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTM1—stomach cancer	1.57e-06	1.4e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CAV1—stomach cancer	1.56e-06	1.39e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AKR1C3—stomach cancer	1.56e-06	1.39e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—APOA1—stomach cancer	1.56e-06	1.39e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL6—stomach cancer	1.53e-06	1.36e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ENO1—stomach cancer	1.52e-06	1.35e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CXCL8—stomach cancer	1.52e-06	1.35e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—MTHFR—stomach cancer	1.52e-06	1.35e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—HRAS—stomach cancer	1.52e-06	1.35e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—HRAS—stomach cancer	1.51e-06	1.34e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PPARG—stomach cancer	1.51e-06	1.34e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—KRAS—stomach cancer	1.5e-06	1.33e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	1.49e-06	1.33e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PIK3CA—stomach cancer	1.49e-06	1.33e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ERCC2—stomach cancer	1.49e-06	1.32e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CDKN1B—stomach cancer	1.48e-06	1.32e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—MTHFR—stomach cancer	1.48e-06	1.32e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ERCC2—stomach cancer	1.47e-06	1.31e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL6—stomach cancer	1.45e-06	1.29e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PIK3CA—stomach cancer	1.44e-06	1.28e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ALB—stomach cancer	1.43e-06	1.28e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCND1—stomach cancer	1.42e-06	1.26e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—JUN—stomach cancer	1.41e-06	1.26e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CAV1—stomach cancer	1.4e-06	1.25e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—APOA1—stomach cancer	1.4e-06	1.24e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—MTHFR—stomach cancer	1.4e-06	1.24e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—stomach cancer	1.39e-06	1.24e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—MTHFR—stomach cancer	1.39e-06	1.23e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HRAS—stomach cancer	1.38e-06	1.23e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PIK3CA—stomach cancer	1.38e-06	1.23e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MMP9—stomach cancer	1.37e-06	1.22e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PPARG—stomach cancer	1.37e-06	1.22e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—NOS3—stomach cancer	1.37e-06	1.22e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CDKN1A—stomach cancer	1.37e-06	1.22e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CAV1—stomach cancer	1.37e-06	1.22e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—APOA1—stomach cancer	1.36e-06	1.21e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ALB—stomach cancer	1.35e-06	1.2e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CD44—stomach cancer	1.35e-06	1.2e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	1.34e-06	1.19e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MAPK8—stomach cancer	1.34e-06	1.19e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—HRAS—stomach cancer	1.33e-06	1.19e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL6—stomach cancer	1.32e-06	1.18e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—NOS3—stomach cancer	1.29e-06	1.15e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CAV1—stomach cancer	1.29e-06	1.15e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—APOA1—stomach cancer	1.29e-06	1.14e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CAV1—stomach cancer	1.28e-06	1.14e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL6—stomach cancer	1.28e-06	1.14e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—APOA1—stomach cancer	1.27e-06	1.13e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—HRAS—stomach cancer	1.27e-06	1.13e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTGS2—stomach cancer	1.25e-06	1.12e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—VEGFA—stomach cancer	1.23e-06	1.1e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PPARG—stomach cancer	1.23e-06	1.1e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—STAT3—stomach cancer	1.22e-06	1.09e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	1.22e-06	1.09e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—IL6—stomach cancer	1.22e-06	1.09e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PPARG—stomach cancer	1.2e-06	1.07e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTGS2—stomach cancer	1.18e-06	1.05e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—NOS3—stomach cancer	1.18e-06	1.05e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MAPK3—stomach cancer	1.17e-06	1.04e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PPP2R1A—stomach cancer	1.15e-06	1.02e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MYC—stomach cancer	1.14e-06	1.01e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PPARG—stomach cancer	1.13e-06	1.01e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTP1—stomach cancer	1.13e-06	1e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PPARG—stomach cancer	1.12e-06	1e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MAPK1—stomach cancer	1.11e-06	9.89e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HMOX1—stomach cancer	1.11e-06	9.87e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ALB—stomach cancer	1.11e-06	9.86e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ALB—stomach cancer	1.08e-06	9.62e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTGS2—stomach cancer	1.08e-06	9.61e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3CA—stomach cancer	1.08e-06	9.58e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—NOS3—stomach cancer	1.06e-06	9.43e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KRAS—stomach cancer	1.05e-06	9.34e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—TYMS—stomach cancer	1.05e-06	9.31e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—NOS3—stomach cancer	1.03e-06	9.21e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTM1—stomach cancer	1.03e-06	9.2e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ALB—stomach cancer	1.02e-06	9.07e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ALB—stomach cancer	1.01e-06	8.99e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—NOS3—stomach cancer	9.75e-07	8.67e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ERCC2—stomach cancer	9.72e-07	8.65e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTGS2—stomach cancer	9.69e-07	8.63e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—NOS3—stomach cancer	9.66e-07	8.6e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CA—stomach cancer	9.64e-07	8.58e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTGS2—stomach cancer	9.46e-07	8.42e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—stomach cancer	9.33e-07	8.3e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—MTHFR—stomach cancer	9.14e-07	8.13e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HRAS—stomach cancer	8.92e-07	7.94e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTGS2—stomach cancer	8.91e-07	7.93e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTGS2—stomach cancer	8.84e-07	7.87e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL6—stomach cancer	8.54e-07	7.6e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CAV1—stomach cancer	8.43e-07	7.5e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—APOA1—stomach cancer	8.41e-07	7.48e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CA—stomach cancer	7.71e-07	6.86e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PPARG—stomach cancer	7.41e-07	6.59e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CA—stomach cancer	7.29e-07	6.49e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALB—stomach cancer	6.66e-07	5.93e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CA—stomach cancer	6.64e-07	5.91e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NOS3—stomach cancer	6.37e-07	5.67e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CA—stomach cancer	5.96e-07	5.31e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTGS2—stomach cancer	5.83e-07	5.19e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CA—stomach cancer	5.82e-07	5.18e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CA—stomach cancer	5.48e-07	4.88e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CA—stomach cancer	5.44e-07	4.84e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CA—stomach cancer	3.59e-07	3.19e-06	CbGpPWpGaD
